A Phase I Open-label, Dose-escalation Trial of PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies
Latest Information Update: 08 Jul 2024
At a glance
- Drugs Anti-CD7 chimeric antigen receptor T-cell therapy-PersonGen Biomedicine (Primary)
- Indications Haematological malignancies; Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors PersonGen Biotherapeutics
Most Recent Events
- 04 Jun 2024 Results (n=12, data cut off: Nov 28th, 2023) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 12 Dec 2023 Preliminary safety and efficacy data for PA3-17 injection in adult r/r T-ALL/LBL patients in a Phase I clinical study presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 29 Apr 2022 According to a PersonGen Biotherapeutics media release, first patient has been infused and treated with PA3-17 in this trial.